As part of the mahi (work) to help manage ADHD medicine supply issues Pharmac is now consulting on a proposal to fund a new methylphenidate product.

This is aimed at addressing the medication shortages and preparing for the upcoming prescriber changes in February 2026.

ADHD New Zealand welcomes this proposal and encourages the ADHD community to submit and have their say.

While medication is just one way for people to manage ADHD and should be used along with other supports, we believe this proposal could make a real difference for those impacted by the shortages.

The consultation details can be found here: 

Proposal to fund a new brand of methylphenidate (pharmac.govt.nz) hydrochloride

The proposal 

Pharmac is proposing to fund Methylphenidate Sandoz XR, a generic version of Concerta, from 1 December 2025, for people with ADHD and narcolepsy.

Consultation closes 5pm, Wednesday 1 October 2025.

Pharmac would value feedback from the ADHD community on this proposal. We encourage our members to submit and share this consultation with their networks.

You can provide feedback through the online form or by emailing consult@pharmac.govt.nz

Proposal to fund a new brand of methylphenidate (pharmac.govt.nz) hydrochloride